Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements



Search results below include Disease and Drug Family Information where your selected drug is a primary subject of discussion.

Arthritis and Inflammation
At least 31.6 million Americans suffer from some form of arthritis. The three most common types are rheumatoid arthritis, osteoarthritis, and gout. Each has a different cause, treatment, and probable outcome.


A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include Drug and Dietary Supplement Profiles where your selected drug is a primary subject of discussion.


Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion.

Patients Infrequently Screened Before Immunosuppressive Specialty Drug Therapy, Study Finds
July 2019
More and more patients are being treated with an expanding array of potent immunosuppressive drugs that require special screening and monitoring to minimize the risk of serious harm. But new research reveals that too many patients receiving these drugs are not undergoing the appropriate screening and monitoring tests.
New Biologic Drugs for Rheumatoid Arthritis: Which Are Safe?
March 2016
Patients with rheumatoid arthritis have a wide array of medication choices for reducing joint pain and inflammation and slowing the progression of joint damage. The most potent such drugs are a group of medications known as disease-modifying anti-rheumatic drugs (DMARDs). Learn about the serious risks posed by these drugs and when they should be used.
Rheumatoid Arthritis Drugs Linked to Increased Shingles Risk
May 2013
The article discusses evidence that five widely used drugs for rheumatoid arthritis can increase the risk of shingles. If you are using one of these drugs, learn what you can do to reduce such risks.
Stronger Liver Toxicity Warning for the Arthritis Drug Leflunomide (ARAVA)
October 2010
On July 13, 2010, the Food and Drug Administration (FDA) announced that the black-box warning for the arthritis drug leflunomide (ARAVA) will be updated to highlight the risk of severe liver injury with the use of this drug and to explain how this risk may be reduced.
Quetiapine (SEROQUEL) Interactions With Other Drugs
February 2010
Quetiapine (SEROQUEL) can interact with 26 different drugs, increasing its blood levels and causing dangerous side effects such as slowed breathing, dizziness and fainting. The article also lists 10 other interacting drugs that can result in lower blood levels, rendering the drug less effective.
Black Box Warnings Updated on Tumor Necrosis Factor Blockers
February 2010
New warnings are being required on CIMZIA, ENBREL, HUMIRA, EMICADE and SIMPONI because of evidence that lymphoma (tumor of lymph tissue) and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.
Heart Failure After Treatment With Etanercept (ENBREL) and Infliximab (REMICADE) - Drugs Used For Rheumatoid Arthritis and Crohn's Disease
July 2003
Staff from the Food and Drug Administration (FDA) and the Duke Clinical Research Institute reviewed 47 cases of heart failure, reported the FDA’s adverse drug reaction reporting system associated with the use of the drugs etanercept (ENBREL) and infliximab (REMICADE), and the results were published in the May 20, 2003 issue of Annals of Internal Medicine.
Two New Warnings! Tuberculosis and Heart Failure with Infliximab (REMICADE)
December 2001
Two new warnings about increased risk of tuberculosis and heart failure were issued for the arthritis drug infliximab (REMICADE) on October 23, 2001. Infliximab is approved by the Food and Drug Administration (FDA) for use in combination with methotrexate (RHEUMATREX), also an arthritis drug, for treating moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate alone.